Skip to content
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Hematology

How Can I Manage Scanxiety During AL Amyloidosis Testing?

At a Glance

Scanxiety and marker anxiety are understandable responses to repeated AL amyloidosis testing. A predictable plan for results, trend-based lab interpretation, moderated support, grounding techniques, and timely mental-health care can make waiting more manageable.

If you experience intense anxiety in the days leading up to your blood tests or while waiting for the results to appear in your portal, you are not alone. Some people use the terms scanxiety or marker anxiety for this feeling, and it is a recognized psychological response to chronic medical testing [1][2]. For patients with AL amyloidosis, coping with this distress involves understanding why the testing process feels so high-stakes, communicating openly with your care team to create a predictable results plan, participating in structured support groups, and learning to track long-term biomarker trends [3][4][5].

Why the “Diagnostic Odyssey” Makes Testing So Hard

To understand why waiting for test results can be deeply distressing, it helps to acknowledge what you have already been through. AL amyloidosis is a rare disease where abnormal plasma cells produce misfolded light chain proteins that deposit in organs [6]. Because its early symptoms can mimic many more common conditions, patients often experience significant diagnostic delays [7].

This long period of uncertainty—often referred to as the diagnostic odyssey—was not your fault and could not necessarily have been prevented by you. However, in some people, delayed recognition can contribute to later-stage presentation or cumulative organ involvement before treatment begins [8]. Given this history, it is completely understandable that regular monitoring can reactivate fear.

What Your Numbers Do (and Do Not) Tell You

If your team checks your labs regularly, it is easy to panic if a single number goes up. In AL amyloidosis, doctors monitor indirect blood markers to assess your hematologic response (whether the abnormal plasma cells are producing fewer light chains) and your organ response (how your heart or kidneys are functioning) [5][9].

Common markers include:

  • iFLC (involved free light chains): The specific type of abnormal light chain your plasma cells overproduce.
  • dFLC (difference in free light chains): The mathematical difference between your involved (abnormal) and uninvolved (normal) light chains [10].
  • NT-proBNP and Troponin: Blood markers that help assess cardiac stress (NT-proBNP) and cardiac injury (troponin). These are not stand-alone measurements of amyloid progression [9].

While it is important to watch these numbers, they should be viewed as long-term trends. Several variables can cause your numbers to bounce around without indicating that your disease is worsening:

  • Unrelated Health Factors: Cardiac markers can fluctuate due to changes in your kidney function, hydration levels, or irregular heartbeats (arrhythmias) [11][12]. (Note: Never deliberately increase or restrict your fluid intake to alter a lab result; always follow your team’s individualized fluid and salt plan.)
  • Different Timelines: Your hematologic response (the drop in light chains) and your organ response do not always happen at the same time [13]. Light chains might improve long before cardiac markers show changes [14].
  • Lab Variations: Serial blood test results can vary slightly depending on the assay equipment used [15]. It is best to compare results from the same laboratory when possible.

When to take action: While minor fluctuations are common, a substantial or sustained change can be clinically meaningful. Do not try to interpret a change on your own, and never ignore severe new symptoms by assuming they are just “noise.” Contact your care team promptly or seek emergency care if you experience new or worsening shortness of breath, chest pain, fainting, severe dizziness, rapid weight gain or swelling, markedly reduced urine, or a racing/irregular heartbeat.

Practical Tools for Managing the Wait

While anxiety can recur around testing time, it often becomes more manageable with a structured plan. Research and patient experience suggest several strategies to help you cope:

  • Create a Predictable Communication Plan: Uncertainty fuels anxiety. Work with your care team to agree on when results will be released and who will explain them. Knowing what to expect may help reduce scanxiety [16][4]. You might also set a specific time to check the portal and turn off push notifications outside of that window.
  • Focus on the Present: Staying grounded in what you can control today may be more beneficial than future-focused “what if” thinking [17]. Brief breathing exercises, planned hobbies, or writing down your questions for the doctor can help lower anxiety while you wait [18].
  • Lean on Structured Support Groups: Connecting with others who understand the disease can provide emotional comfort and practical information [19]. However, unmoderated online spaces can sometimes increase distress [20]. Look for moderated, disease-specific groups (such as Amyloidosis Support Groups), and remember that online peers cannot replace your treating team’s medical advice [21].
  • Seek Professional Mental Health Support: If anxiety is disrupting your sleep, appetite, or ability to function, seek support early. A psycho-oncologist (a mental-health professional familiar with cancer and blood disorders), counselor, or social worker can teach you targeted coping skills [22]. If your anxiety becomes disabling, or if you experience severe panic or thoughts of self-harm, contact a clinician or local crisis service immediately.

Common questions in this guide

What are scanxiety and marker anxiety in AL amyloidosis?
Scanxiety and marker anxiety describe intense worry before a medical test or while waiting for results. In AL amyloidosis, repeated blood testing and past uncertainty about the diagnosis can make this distress feel especially high-stakes, but anxiety alone does not show that the disease is worsening.
Can one abnormal AL amyloidosis lab result mean that my disease is getting worse?
Not necessarily. Markers such as involved free light chains, the difference between involved and uninvolved light chains, NT-proBNP, and troponin are interpreted as trends and in context because kidney function, hydration, heart rhythm, and laboratory methods can affect results. Ask your care team whether a change is substantial or persistent enough to require action.
How can I make waiting for AL amyloidosis test results less stressful?
Ask your care team to agree on when results will be released and who will explain them, then choose a limited time to check your patient portal. Breathing exercises, planned activities, writing down questions, and moderated disease-specific support groups may also make the waiting period easier.
Which symptoms should prompt me to contact my AL amyloidosis care team?
Contact your care team promptly for new or worsening shortness of breath, chest pain, fainting, severe dizziness, rapid weight gain or swelling, markedly reduced urine, or a racing or irregular heartbeat. Seek emergency care for severe or rapidly worsening symptoms rather than waiting for the next blood test.
Should my AL amyloidosis blood tests be done at the same laboratory each time?
Using the same laboratory when possible can make results easier to compare because testing methods and equipment may vary. If insurance or logistics require a different laboratory, tell your care team so they can interpret the change appropriately.
When should I seek professional help for AL amyloidosis testing anxiety?
Consider speaking with a psycho-oncologist, counselor, or social worker if testing anxiety disrupts your sleep, appetite, or daily functioning. Disabling panic or thoughts of self-harm require immediate contact with a clinician or local crisis service.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Can we set a predictable schedule for how and when I will receive my lab results so I am not endlessly checking the portal?
  2. 2.When looking at my dFLC and NT-proBNP, how do we distinguish between expected variation and a clinically meaningful change that requires action?
  3. 3.What specific symptoms—like changes in my breathing, weight, or heart rate—should prompt me to call you rather than waiting for my next lab test?
  4. 4.Should my blood tests always be done at the exact same laboratory, and how should I handle it if my insurance requires a change?
  5. 5.Is there a psycho-oncologist, social worker, or specialized counselor on our care team that I can speak with about my testing anxiety?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Prevalence, severity, and modifiable predictors of scanxiety in patients undergoing routine oncologic imaging: a prospective longitudinal study.

    Shah MS, Memon JA, Malik U, et al.

    Clinical imaging 2025; (128()):110634 doi:10.1016/j.clinimag.2025.110634.

    PMID: 41077027
  2. 2

    Prevalence and severity of scanxiety in people with advanced cancers: a multicentre survey.

    Bui KT, Kiely BE, Dhillon HM, et al.

    Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 2022; (30(1)):511-519 doi:10.1007/s00520-021-06454-9.

    PMID: 34333717
  3. 3

    Scanxiety among Adults with Cancer: A Scoping Review to Guide Research and Interventions.

    Derry-Vick HM, Heathcote LC, Glesby N, et al.

    Cancers 2023; (15(5)) doi:10.3390/cancers15051381.

    PMID: 36900174
  4. 4

    "You Always Worry": Scan-Related Anxiety Among Patients With Metastatic Lung Cancer.

    Derry-Vick H, Prigerson HG, Hahne J, et al.

    Journal of the American College of Radiology : JACR 2025; (22(12)):1572-1577 doi:10.1016/j.jacr.2025.08.021.

    PMID: 41338711
  5. 5

    Time to Redefine Risk-Stratification and Response Criteria in Immunoglobulin Light Chain Amyloidosis?

    Jain A, Ramasamy K

    Clinical lymphoma, myeloma & leukemia 2020; (20(10)):e769-e776 doi:10.1016/j.clml.2020.05.025.

    PMID: 32653456
  6. 6

    Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.

    Muchtar E, Buadi FK, Dispenzieri A, Gertz MA

    Acta haematologica 2016; (135(3)):172-90 doi:10.1159/000443200.

    PMID: 26771835
  7. 7

    Immunoglobulin Light-Chain Amyloidosis: Clinical Presentations and Diagnostic Approach.

    Hwa YL, Fogaren T, Sams A, et al.

    Journal of the advanced practitioner in oncology 2019; (10(5)):470-481 doi:10.6004/jadpro.2019.10.5.5.

    PMID: 33457060
  8. 8

    Amyloidosis: a case series and review of the literature.

    Senecal JB, Abou-Akl R, Allevato P, et al.

    Journal of medical case reports 2023; (17(1)):184 doi:10.1186/s13256-023-03886-1.

    PMID: 37081462
  9. 9

    Natriuretic Peptides and Cardiac Troponins: Markers of Disease Progression and Risk in Light Chain Cardiac Amyloidosis.

    Wees I, Hendren NS, Kaur G, et al.

    Current heart failure reports 2023; (20(5)):350-357 doi:10.1007/s11897-023-00616-y.

    PMID: 37428428
  10. 10

    Treatment response measurements and survival outcomes in a cohort of newly diagnosed AL amyloidosis.

    Jimenez-Zepeda VH, Lee H, McCulloch S, et al.

    Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis 2021; (28(3)):182-188 doi:10.1080/13506129.2021.1921725.

    PMID: 34096429
  11. 11

    Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia.

    Dittrich T, Benner A, Kimmich C, et al.

    Haematologica 2019; (104(7)):1451-1459 doi:10.3324/haematol.2018.205336.

    PMID: 30655373
  12. 12

    Systemic immunoglobulin light chain amyloidosis.

    Merlini G, Dispenzieri A, Sanchorawala V, et al.

    Nature reviews. Disease primers 2018; (4(1)):38 doi:10.1038/s41572-018-0034-3.

    PMID: 30361521
  13. 13

    Organ responses with daratumumab therapy in previously treated AL amyloidosis.

    Chung A, Kaufman GP, Sidana S, et al.

    Blood advances 2020; (4(3)):458-466 doi:10.1182/bloodadvances.2019000776.

    PMID: 32027745
  14. 14

    Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis.

    Salinaro F, Meier-Ewert HK, Miller EJ, et al.

    European heart journal. Cardiovascular Imaging 2017; (18(9)):1057-1064 doi:10.1093/ehjci/jew298.

    PMID: 27965280
  15. 15

    Effect of specimen type on free immunoglobulin light chains analysis on the Roche Diagnostics cobas 8000 analyzer.

    Nelson LS, Steussy B, Morris CS, Krasowski MD

    SpringerPlus 2015; (4()):760 doi:10.1186/s40064-015-1546-x.

    PMID: 26682113
  16. 16

    Effectiveness of Nurse-Led Psychoeducation on Knowledge and Psychological Distress in Cancer Patients Undergoing Radiological Imaging: A Randomized Controlled Trial.

    Dahiya A, Joshi P, Tiwari SK, et al.

    Psycho-oncology 2025; (34(5)):e70164 doi:10.1002/pon.70164.

    PMID: 40320568
  17. 17

    Coping With 'Scanxiety': Within-Person Processes in Lung Cancer.

    Dunsmore VJ, Neupert SD

    Psychological reports 2025; (128(2)):702-722 doi:10.1177/00332941231164336.

    PMID: 36964680
  18. 18

    Scanxiety: a scoping review about scan-associated anxiety.

    Bui KT, Liang R, Kiely BE, et al.

    BMJ open 2021; (11(5)):e043215 doi:10.1136/bmjopen-2020-043215.

    PMID: 34039571
  19. 19

    How Cancer Online Support Groups Work, for Whom, and in What Circumstances: Realist Review.

    Bender JL, Scruton S, Wong G, et al.

    Journal of medical Internet research 2026; (28()):e77445 doi:10.2196/77445.

    PMID: 42127226
  20. 20

    Peer support interventions for breast cancer patients: a systematic review.

    Hu J, Wang X, Guo S, et al.

    Breast cancer research and treatment 2019; (174(2)):325-341 doi:10.1007/s10549-018-5033-2.

    PMID: 30600413
  21. 21

    The benefits and challenges of established peer support programmes for patients, informal caregivers, and healthcare providers.

    Joo JH, Bone L, Forte J, et al.

    Family practice 2022; (39(5)):903-912 doi:10.1093/fampra/cmac004.

    PMID: 35104847
  22. 22

    Multimodal psychosocial intervention for family caregivers of patients undergoing hematopoietic stem cell transplantation: A randomized clinical trial.

    El-Jawahri A, Jacobs JM, Nelson AM, et al.

    Cancer 2020; (126(8)):1758-1765 doi:10.1002/cncr.32680.

    PMID: 31899552

This page is for informational purposes only and does not constitute medical advice. Your AL amyloidosis team should interpret your results and advise you about urgent symptoms or mental-health support.

Get notified when new evidence is published on AL amyloidosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.